Stock Analysis

Earnings Miss: Mani, Inc. Missed EPS By 13% And Analysts Are Revising Their Forecasts

TSE:7730
Source: Shutterstock

Mani, Inc. (TSE:7730) just released its latest quarterly report and things are not looking great. Mani missed earnings this time around, with JP¥7.5b revenue coming in 3.0% below what the analysts had modelled. Statutory earnings per share (EPS) of JP¥13.34 also fell short of expectations by 13%. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. We thought readers would find it interesting to see the analysts latest (statutory) post-earnings forecasts for next year.

earnings-and-revenue-growth
TSE:7730 Earnings and Revenue Growth July 13th 2025

Taking into account the latest results, the consensus forecast from Mani's seven analysts is for revenues of JP¥31.8b in 2026. This reflects a solid 8.9% improvement in revenue compared to the last 12 months. Statutory earnings per share are predicted to soar 21% to JP¥67.25. In the lead-up to this report, the analysts had been modelling revenues of JP¥32.0b and earnings per share (EPS) of JP¥68.34 in 2026. So it's pretty clear that, although the analysts have updated their estimates, there's been no major change in expectations for the business following the latest results.

See our latest analysis for Mani

With no major changes to earnings forecasts, the consensus price target fell 5.1% to JP¥1,405, suggesting that the analysts might have previously been hoping for an earnings upgrade. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. The most optimistic Mani analyst has a price target of JP¥1,800 per share, while the most pessimistic values it at JP¥1,100. This shows there is still a bit of diversity in estimates, but analysts don't appear to be totally split on the stock as though it might be a success or failure situation.

One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. It's pretty clear that there is an expectation that Mani's revenue growth will slow down substantially, with revenues to the end of 2026 expected to display 7.1% growth on an annualised basis. This is compared to a historical growth rate of 15% over the past five years. Juxtapose this against the other companies in the industry with analyst coverage, which are forecast to grow their revenues (in aggregate) 5.6% per year. Even after the forecast slowdown in growth, it seems obvious that Mani is also expected to grow faster than the wider industry.

Advertisement

The Bottom Line

The most important thing to take away is that there's been no major change in sentiment, with the analysts reconfirming that the business is performing in line with their previous earnings per share estimates. Fortunately, they also reconfirmed their revenue numbers, suggesting that it's tracking in line with expectations. Additionally, our data suggests that revenue is expected to grow faster than the wider industry. The consensus price target fell measurably, with the analysts seemingly not reassured by the latest results, leading to a lower estimate of Mani's future valuation.

With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have estimates - from multiple Mani analysts - going out to 2027, and you can see them free on our platform here.

We don't want to rain on the parade too much, but we did also find 1 warning sign for Mani that you need to be mindful of.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About TSE:7730

Mani

Engages in the manufacture and distribution of medical devices and dental instruments in Japan and internationally.

Flawless balance sheet with moderate growth potential.

Advertisement